Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
暂无分享,去创建一个
C. Bloomfield | K. Döhner | R. Schlenk | H. Döhner | M. Heuser | A. Ganser | R. Larson | J. Sierra | M. Voso | S. Mandrekar | F. Appelbaum | A. Benner | D. Niederwieser | M. Tallman | R. Stone | A. Wei | M. Sanz | G. Marcucci | T. Prior | H. Serve | J. Jansen | J. Nomdedéu | G. Ehninger | J. Brandwein | J. Krauter | C. Thiede | T. D. de Witte | I. Gathmann | S. Amadori | C. Pallaud | R. Klisovic | B. Medeiros | T. Ottone | Dan Jones | N. Jahn | E. Panina | A. Gambietz | Nikolaus Jahn
[1] R. Greil,et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. , 2019, Blood.
[2] R. Stone. What FLT3 inhibitor holds the greatest promise? , 2018, Best practice & research. Clinical haematology.
[3] C. Bloomfield,et al. FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) , 2018, Blood.
[4] C. Bloomfield,et al. Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) , 2018, Blood.
[5] Tamara J. Blätte,et al. Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) , 2018, Blood.
[6] J. Kanda,et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. , 2018, Blood advances.
[7] P. Furet,et al. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy. , 2018, Biochemistry.
[8] Torsten Haferlach,et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.
[9] R. Larson,et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. , 2018, Blood advances.
[10] H. Putter,et al. Prediction errors for state occupation and transition probabilities in multi‐state models , 2018, Biometrical journal. Biometrische Zeitschrift.
[11] C. Bloomfield,et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.
[12] M. Levis,et al. The Future of Targeting FLT3 Activation in AML , 2017, Current Hematologic Malignancy Reports.
[13] Lars Bullinger,et al. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[15] E. Vellenga,et al. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio , 2016, Leukemia.
[16] H. Kantarjian,et al. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[18] S. Iacobelli,et al. Survival probabilities with time‐dependent treatment indicator: quantities and non‐parametric estimators , 2016, Statistics in medicine.
[19] N. Schmitz,et al. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] D. Grimwade,et al. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.
[21] L. Bullinger,et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.
[22] R. Hills,et al. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. , 2014, Blood.
[23] J. Esteve,et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.
[24] K. Döhner,et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Erdogan Taskesen,et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.
[26] K. Döhner,et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.
[27] T. Haferlach,et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. , 2009, Blood.
[28] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[29] Adam J Mead,et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.
[30] M. Schumacher,et al. Consistent Estimation of the Expected Brier Score in General Survival Models with Right‐Censored Event Times , 2006, Biometrical journal. Biometrische Zeitschrift.
[31] Stefan Fröhling,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.
[32] C. Bloomfield,et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Axel Benner,et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.
[35] G. Ehninger,et al. Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .
[36] M. Caligiuri,et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.
[37] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[38] Ren Johansen. An Empirical Transition Matrix for Non-homogeneous Markov Chains Based on Censored Observations , 1978 .
[39] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[40] D.,et al. Regression Models and Life-Tables , 2022 .